Tarek Meniawy

12PUBLICATIONS
72CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Sep 02, 2025
Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study.

Kaamini Planisamy, Elena Ctori, Benhur Amanuel

|Jan 04, 2024
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

John M Kirkwood, Michele Del Vecchio, Jeffrey Weber

|Nov 04, 2023
Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

John M Kirkwood, Michele Del Vecchio, Jeffrey Weber

|Oct 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

John M Kirkwood, Michele Del Vecchio, Jeffrey Weber

|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

Reinhard Dummer, Pippa Corrie, Ralf Gutzmer

Pageof 2

Frequent Collaborators

5 joint publications

Georgina V Long

4 joint publications

Paolo A Ascierto

3 joint publications

Christoph Hoeller

3 joint publications

John M Kirkwood